adminJenene Thomas
Okay. We are ready to get started, and welcome, everyone, to the Akari Therapeutics Corporate Update Webcast. [Operator Instructions] Note that this webcast is being recorded at the company’s request, and a replay will be made available on the company’s website following the end of the event.
At this time, I’d like to remind our listeners that remarks made during this webcast may state management’s intentions, beliefs, expectations or future projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws and are based on Akari Therapeutics current expectations, and actual results could differ materially.
As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the periodic reports Akari Therapeutics files with the Securities and Exchange Commission. These documents are available in the Investors section of the company’s website and on the Securities and Exchange Commission’s website, and we encourage you to review these documents carefully.
So joining on today’s call from the Akari Therapeutics leadership team are Abizer Gaslightwala, he is President and Chief Executive Officer; and Dr. Satyajit Mitra, he is Head of Oncology.
I would now like to turn the call over to Abizer. Please proceed.
Abizer Gaslightwala
CEO, President & Director
Great. Well, thank you, Jenene, and welcome, everyone. We thank you for joining us today.
Go to the next slide, please. So I’m just going to
Read the full article here
